BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (I) therapy: Should we modify our therapeutic strategy?

Introduction: The BRAF V600E mutation in papillary thyroid cancer (PTC) has been associated with resistance to I. Our aim was to quantify the response to I after surgery in patients who had the mutation (BRAF+) and those who did not have the mutated gene (BRAF-).

Method: A prospective cohort study was designed, from September 2015 to February 2016, which included patients with PTC receiving therapy after surgical treatment.

[Primary hyperparathyroidism and acute toxic hypercalcaemic crisis].

Objectives: To describe the clinical characteristics and surgical treatment of patients with acute hypercalcaemia due to primary hyperparathyroidism (PHPT) and compare them with other patients with PHPT without associated acute hypercalcaemia.

Material And Methods: A prospective, observational study (1998-2010) was conducted on 158 patients with PHPT treated by parathyroidectomy. Those with acute hypercalcaemia (>14 mg/dl -3.